基于智能丝的现场Sol-Gel调节直肠微环境,有效缓解性结肠炎
Perumal Ramesh Kannan1,2, Liuting Chen1,2, Yudie Lv1,2
1Institute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou, 310018, P. R. China.
Advanced healthcare materials
|May 21, 2025
概括
一种基于丝纤维素的新的fucoidan凝有效地治疗性结肠炎 (UC),通过减少炎症,改善肠道屏障功能,并在小鼠模型中恢复粘膜完整性.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种与结直肠癌相关的慢性炎症性肠病.
- 目前的UC治疗侧重于炎症,但忽视了对愈合至关重要的微环境因素.
- 粘膜愈合障碍和微环境调节障碍导致UC治疗失败.
研究的目的:
- 开发和评估一种基于丝纤维素的新型乳腺 (SFU) 在位直肠凝用于UC治疗.
- 在临床前UC模型中评估SFU的抗氧化,抗炎和粘膜愈合特性.
主要方法:
- 风湿学分析证实了SFU凝在生理条件下的sol-gel过渡.
- 在体外评估抗氧化活性 (DPPH激素清除,ROS,NO抑制).
- 在硫酸盐 (DSS) 诱导的UC小鼠模型中评估SFU的疗效,评估临床症状,炎症标志物,巨细胞极化和肠道屏障完整性.
主要成果:
- SFU凝表现出显著的抗氧化活性,具有73.3%的DPPH基因清除率.
- 在小鼠中,SFU治疗缓解了UC症状,降低了体重减轻和疾病活性指数 (DAI).
- SFU治疗促进了M2巨分化,降低了IL-6和TNF-α,增强了紧结蛋白 (Occludin-1,ZO-1),恢复了杯状细胞和粘素,并预防了纤维化.
结论:
- SFU直肠凝是治疗性结肠炎的一种有前途的治疗剂.
- SFU表现出强大的抗氧化和抗炎作用,促进肠道粘膜的愈合和屏障恢复.
- SFU代表了UC的潜在自然疗法,解决了微环境因素以改善治疗结果.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
114
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
114
01:21Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
01:21Inflammatory Bowel Disease V: Surgical Management
71
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
71
01:17Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
01:20Drugs Affecting GI Tract Motility: Other Laxatives
141
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
141
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
201
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
201